Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12876612 | 1.00 | TSHR (0.60) | TSHRALDH1A1SLC18A3EPHX2SHBG | |
| SCHEMBL17070218 | 0.97 | TSHR (0.56) | TSHRALDH1A1SLC18A3EPHX2SHBG | |
| SCHEMBL9396681 | 0.97 | TSHR (0.56) | TSHRALDH1A1SLC18A3EPHX2SHBG | |
| SCHEMBL12428113 | 0.97 | TSHR (0.56) | TSHRALDH1A1SLC18A3EPHX2SHBG | |
| SCHEMBL787666 | 0.97 | TSHR (0.56) | TSHRALDH1A1SLC18A3EPHX2SHBG | |
| SCHEMBL219048 | 0.89 | TSHR (0.50) | TSHRALDH1A1EPHX2SHBGESR2 | |
| SCHEMBL7799823 | 0.89 | TSHR (0.50) | TSHRALDH1A1EPHX2SHBGESR2 | |
| SCHEMBL7077398 | 0.89 | TSHR (0.50) | TSHRALDH1A1EPHX2SHBGESR2 | |
| SCHEMBL10879751 | 0.89 | TSHR (0.50) | TSHRALDH1A1EPHX2SHBGESR2 | |
| Biphenyl SCHEMBL6720507 | 0.86 | TSHR (0.71) | TSHRALDH1A1SLC18A3CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250043047-A1 | POLYMERIZABLE MONOMERS AND METHOD OF POLYMERIZING THE SAME | ALIGN TECHNOLOGY INC (US) | 2025-02-06 | — | — | US | disclosed |
| CN-116640061-A | Polymerizable monomer and polymerization method thereof | 阿莱恩技术有限公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-112074544-B | Polymerizable monomer and polymerization method thereof | 阿莱恩技术有限公司 | 2023-06-13 | — | — | CN | disclosed |
| US-20230024516-A1 | ISOQUINOLINONE DERIVATIVES SERVING AS ROCK PROTEIN KINASE INHIBITORS AND USE THEREOF | GUANGZHOU OCUSUN OPHTHALMIC BIOTECHNOLOGY CO., LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| EP-3800176-A1 | NOVEL POLYMERISABLE MONOMERS AND THEIR USE AS REACTIVE DILUENTS IN CURABLE COMPOSITIONS | Align Technology, Inc. (US) | 2021-04-07 | — | — | EP | disclosed |
| US-20210002396-A1 | POLYMERIZABLE MONOMERS AND METHOD OF POLYMERIZING THE SAME | ALIGN TECHNOLOGY, INC. | 2021-01-07 | — | — | US | disclosed |
| CN-112074544-A | Polymerizable monomer and polymerization method thereof | 阿莱恩技术有限公司 | 2020-12-11 | — | — | CN | disclosed |
| EP-3564206-B1 | NOVEL POLYMERISABLE MONOMERS AND THEIR USE AS REACTIVE DILUENTS IN CURABLE COMPOSITIONS | ALIGN TECHNOLOGY INC (US) | 2020-11-04 | — | — | EP | disclosed |
| EP-3564206-B1 | NOVEL POLYMERISABLE MONOMERS AND THEIR USE AS REACTIVE DILUENTS IN CURABLE COMPOSITIONS | ALIGN TECHNOLOGY INC (US) | 2020-11-04 | — | — | EP | disclosed |
| US-10781275-B2 | Polymerizable monomers and method of polymerizing the same | ALIGN TECHNOLOGY, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20130012434-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME CORP. | 2013-01-10 | — | — | US | disclosed |
| US-20130012434-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME CORP. | 2013-01-10 | — | — | US | disclosed |
| US-8269043-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120190649-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190649-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2012-07-26 | — | — | US | disclosed |
| WO-2011119559-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | SCHERING CORPORATION (US) | 2011-09-29 | — | — | WO | disclosed |
| EP-2364088-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | Biogen Idec MA Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110003395-A1 | SPECIFIC ANALYSIS OF ANALYTES USING REAGENT COMPOUNDS, LABELING STRATEGIES, AND MASS SPECTROMETRY WORKFLOW | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2011-01-06 | — | — | US | disclosed |
| US-20100160258-A1 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2010051030-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160258-A1 | Bicyclic aryl sphingosine 1-phosphate analogs | S1PR1, S1PR3, S1PR4 | TSHR 452/4885ALDH1A1 3931/4885SLC18A3 3169/4885 |
| US-20120190649-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR3, S1PR4 | TSHR 452/4885ALDH1A1 3931/4885SLC18A3 3169/4885 |
| US-20130012434-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | TSHR 44/4885ALDH1A1 1773/4885SLC18A3 4797/4885 |
| US-20230024516-A1 | ISOQUINOLINONE DERIVATIVES SERVING AS ROCK PROTEIN KINASE INHIBITORS AND USE THEREOF | ROCK1, ROCK2, CIT | TSHR 4222/4885ALDH1A1 2665/4885SLC18A3 2650/4885 |
| US-20110003395-A1 | SPECIFIC ANALYSIS OF ANALYTES USING REAGENT COMPOUNDS, LABELING STRATEGIES, AND MASS SPECTROMETRY WORKFLOW | HSD17B7, HSD17B13, HSD11B1 | TSHR 2467/4885ALDH1A1 70/4885SLC18A3 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.